| Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ—Transition Readiness Assessment Questionnaire GS Sawicki, K Lukens-Bull, X Yin, N Demars, IC Huang, W Livingood, ... Journal of pediatric psychology 36 (2), 160-171, 2011 | 615 | 2011 |
| High treatment burden in adults with cystic fibrosis: challenges to disease self-management GS Sawicki, DE Sellers, WM Robinson Journal of cystic fibrosis 8 (2), 91-96, 2009 | 543 | 2009 |
| The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity DL Wood, GS Sawicki, MD Miller, C Smotherman, K Lukens-Bull, ... Academic pediatrics 14 (4), 415-422, 2014 | 415 | 2014 |
| Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study JC Davies, S Cunningham, WT Harris, A Lapey, WE Regelmann, ... The Lancet Respiratory Medicine 4 (2), 107-115, 2016 | 348 | 2016 |
| Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR … MW Konstan, EF McKone, RB Moss, G Marigowda, S Tian, D Waltz, ... The lancet Respiratory medicine 5 (2), 107-118, 2017 | 318 | 2017 |
| Cystic fibrosis and transition to adult medical care LK Tuchman, LA Schwartz, GS Sawicki, MT Britto Pediatrics 125 (3), 566-573, 2010 | 269 | 2010 |
| Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study M Rosenfeld, CE Wainwright, M Higgins, LT Wang, C McKee, D Campbell, ... The lancet respiratory medicine 6 (7), 545-553, 2018 | 258 | 2018 |
| Obesity and airway dysanapsis in children with and without asthma E Forno, DJ Weiner, J Mullen, G Sawicki, G Kurland, YY Han, MM Cloutier, ... American journal of respiratory and critical care medicine 195 (3), 314-323, 2017 | 258 | 2017 |
| Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data GS Sawicki, EF McKone, DJ Pasta, SJ Millar, JS Wagener, CA Johnson, ... American journal of respiratory and critical care medicine 192 (7), 836-842, 2015 | 253 | 2015 |
| Necrotising pneumonia is an increasingly detected complication of pneumonia in children GS Sawicki, FL Lu, C Valim, RH Cleveland, AA Colin European Respiratory Journal 31 (6), 1285-1291, 2008 | 250 | 2008 |
| Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries N Volkova, K Moy, J Evans, D Campbell, S Tian, C Simard, M Higgins, ... Journal of Cystic Fibrosis 19 (1), 68-79, 2020 | 244 | 2020 |
| Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample AL Quittner, GS Sawicki, A McMullen, L Rasouliyan, DJ Pasta, A Yegin, ... Quality of Life Research 21, 1267-1278, 2012 | 235 | 2012 |
| Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor L Bessonova, N Volkova, M Higgins, L Bengtsson, S Tian, C Simard, ... Thorax 73 (8), 731-740, 2018 | 207 | 2018 |
| Transition care: future directions in education, health policy, and outcomes research N Sharma, K O’Hare, RC Antonelli, GS Sawicki Academic pediatrics 14 (2), 120-127, 2014 | 178 | 2014 |
| Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes GS Sawicki, CL Ren, MW Konstan, SJ Millar, DJ Pasta, AL Quittner, ... Journal of Cystic Fibrosis 12 (5), 461-467, 2013 | 161 | 2013 |
| Longitudinal assessment of health‐related quality of life in an observational cohort of patients with cystic fibrosis GS Sawicki, L Rasouliyan, AH McMullen, JS Wagener, SA McColley, ... Pediatric pulmonology 46 (1), 36-44, 2011 | 141 | 2011 |
| Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution GS Sawicki, JE Signorovitch, J Zhang, D Latremouille‐Viau, ... Pediatric pulmonology 47 (1), 44-52, 2012 | 136 | 2012 |
| Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an … JJ McNamara, SA McColley, G Marigowda, F Liu, S Tian, CA Owen, ... The Lancet Respiratory Medicine 7 (4), 325-335, 2019 | 135 | 2019 |
| Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives GS Sawicki, KS Heller, N Demars, WM Robinson Pediatric pulmonology 50 (2), 127-136, 2015 | 135 | 2015 |
| Managing treatment complexity in cystic fibrosis: challenges and opportunities GS Sawicki, H Tiddens Pediatric pulmonology 47 (6), 523-533, 2012 | 135 | 2012 |
